查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1938784

狂犬病诊断市场－全球产业规模、份额、趋势、机会及预测（依诊断方法、技术、地区及竞争格局划分，2021-2031年）

Rabies Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnostic Method, By Technology Method, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球狂犬病诊断市场预计将从 2025 年的 27.8 亿美元成长到 2031 年的 44.6 亿美元，复合年增长率为 8.20%。

此细分市场包括体外诊断研究调查方法，例如直接萤光抗体检测 (DFA)、聚合酵素链锁反应(PCR) 和酵素免疫分析法(ELISA)，这些方法用于检测人类和动物检体中的通用病毒。市场扩张的主要原因是感染疾病发病率的上升以及旨在消除犬源性狂犬病的「同一健康」倡议的加强。此外，宠物主人数量的增加以及政府对动物疫苗接种和跨境运输的严格监管也推动了对快速、准确诊断工具的需求。

市场概览
预测期 2027-2031
市场规模：2025年 27.8亿美元
市场规模：2031年 44.6亿美元
复合年增长率：2026-2031年 8.2%
成长最快的细分市场 萤光抗体技术（FAT）
最大的市场 北美洲

市场发展的主要障碍在于先进诊断技术成本高昂，以及开发中国家（疾病负担最重）缺乏检测基础设施。这种不公平现象限制了资源匮乏地区广泛采用先进检测通讯协定。根据美国兽医协会 (AVMA) 2024 年的报告，在上一个监测期内，美国提交了约 89,530 份动物检体进行狂犬病检测。这些数据凸显了持续监测的重要性，同时也显示新兴市场的资金限制仍限制全球取得这些关键诊断资源。

市场驱动因素

旨在2030年消除狂犬病的国际策略倡议正在透过确保资金投入和优先开展地方性流行地区的监测工作，显着改变狂犬病的诊断格局。国际组织正在加速将狂犬病控制纳入更全面的卫生投资框架，为永续的市场成长奠定基础。作为这项转变的象征，世界卫生组织（世卫组织）于2024年6月宣布，全球疫苗免疫倡议（Gavi）董事会已核准将用于暴露后免疫的人用狂犬病疫苗纳入其投资策略。预计这项决定将系统性地改善目标国家的治疗可近性，并需要改进诊断追踪。这项策略调整旨在应对狂犬病带来的巨大经济影响。 2024年8月，美国农业部估计，光是在美国，狂犬病的检测、预防和控制的年度总成本就将超过5亿美元。

同时，分子诊断和侧向流动诊断技术的进步，透过提供快速、经济且适用于各种检测环境的选择，正在扩大市场进入。製造商正积极开发和推出基于免疫检测的解决方案，以减少对复杂实验室设备的依赖，从而提高兽医和人类医疗保健领域的检测效率。例如，2024年2月，百奥通动物保健公司宣布推出AsurDx狂犬病抗体检测试剂盒，这是一款基于酶联免疫吸附试验（ELISA）的产品，旨在快速检测哺乳动物血清中的狂犬病毒抗体。这些创新对于满足日益增长的有效疫苗监测和疾病监测需求至关重要，并确保诊断能力与全球根除狂犬病的目标一致。

市场挑战

先进诊断技术的高昂成本，加上开发中国家实验室基础设施的匮乏，是全球狂犬病诊断市场发展的主要障碍。聚合酵素链锁反应(PCR) 和直接萤光抗体检测 (DFA) 等先进技术灵敏度极高，但需要大量的设备、可靠的电力供应和专业人员投入。在狂犬病高发生率的资源匮乏地区，这些先决条件往往难以满足，造成了经济差距。这种差距有效地阻碍了可靠检测套组的普及，迫使医疗系统依赖临床观察，而非购买诊断试剂盒。

因此，在理论上疾病负担最重的地区，市场渗透十分困难，产生收入往往仅限于拥有成熟监测网络的已开发国家。未能进入高负担国家会限制全球贸易，并阻碍製造商在新兴经济体拓展分销网络。世界卫生组织（世卫组织）估计，到2024年，狂犬病造成的全球经济负担约为每年86亿美元，这一数据凸显了严重的财政限制，这些限制制约了这些地区卫生系统采购必要诊断设备的能力。

市场趋势

为了支持精准的流行病学追踪，市场越来越重视基因序列测定和变异分型，而非简单的病毒存在/缺失检测。实验室正从传统的直接萤光抗体（DFA）检测转向分子表征，以识别特定的病毒谱系并监测跨物种传播途径。这一转变使公共卫生官员能够区分传统型株和引入性变异株，这对于在非流行地区制定有针对性的干预策略至关重要。根据美国兽医协会（AVMA）于2025年7月发布的《2023年美国狂犬病监测报告》，35.6%的阳性检体接受了病毒表征以识别特定变异株，这表明疾病管理越来越依赖先进的分子技术。

一个值得关注的趋势是扩大监测范围，以捕捉对都市区和近郊居民构成持续威胁的野生动物宿主。与以往以家畜为中心的模式不同，这些扩展后的监测网络专注于监测特定的野生动物媒介，例如蝙蝠和狐狸，它们在犬类狂犬病已被控制的地区是主要的宿主。这种转变需要将本地数据整合到更广泛的国家追踪系统中，以便及早发现疫情爆发。例如，根据加拿大动物健康监测系统于2025年2月发布的“狂犬病疫情最新情况”，2024年安大略省确诊的蝙蝠传播狂犬病病例数达到91例，这凸显了持续开展野生动物监测对于防止狂犬病再次传入家畜种群至关重要。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球狂犬病诊断市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 透过诊断方法（萤光抗体试验（FAT）、免疫组织化学、扩增法、组织学、血清学）
    • 依技术（ELISA/免疫组织化学、层析法技术、PCR 等）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美狂犬病诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲狂犬病诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区狂犬病诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲狂犬病诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章 南美洲狂犬病诊断市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球狂犬病诊断市场：SWOT分析

第十四章 波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Bio-Rad Laboratories, Inc
  • Merck KGaA
  • Aviva Systems Biology Corporation.
  • Creative Diagnostics
  • Demeditec Diagnostics GmbH.
  • Abbexa Ltd.
  • Norgen Biotek Corp.
  • BioNote, Inc.
  • Express Biotech International Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19870

The Global Rabies Diagnostics Market is projected to increase from a valuation of USD 2.78 Billion in 2025 to USD 4.46 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 8.20%. This market segment includes in vitro diagnostic methodologies such as Direct Fluorescent Antibody (DFA) testing, Polymerase Chain Reaction (PCR), and Enzyme-Linked Immunosorbent Assays (ELISA), which are utilized to detect the rabies virus in specimens from both humans and animals. Market expansion is largely fueled by the rising incidence of zoonotic diseases and intensified "One Health" efforts aimed at eradicating dog-mediated rabies. Additionally, growing rates of pet ownership and the enforcement of strict government mandates regarding animal vaccination and cross-border transport are boosting the demand for fast and precise diagnostic tools.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.78 Billion
Market Size 2031USD 4.46 Billion
CAGR 2026-20318.2%
Fastest Growing SegmentFluorescent Antibody Test (FAT)
Largest MarketNorth America

A major obstacle hindering market progress is the prohibitive cost of advanced diagnostic technologies combined with the insufficiency of laboratory infrastructure in developing nations, where the burden of disease is most severe. This inequality restricts the broader application of sophisticated testing protocols in resource-limited areas. As reported by the American Veterinary Medical Association in 2024, approximately 89,530 animal specimens were submitted for rabies testing within the United States during the preceding surveillance interval. While such figures underscore the essential nature of consistent surveillance, financial limitations in emerging markets persist in limiting global access to these critical diagnostic resources.

Market Driver

Strategic international initiatives designed to achieve rabies elimination by 2030 are significantly transforming the diagnostics landscape by securing funding and prioritizing surveillance in endemic zones. Global organizations are increasingly incorporating rabies control into comprehensive healthcare investment frameworks, establishing a solid foundation for sustainable market growth. Highlighting this shift, the World Health Organization noted in June 2024 that the Gavi Board approved the addition of human rabies vaccines for post-exposure prophylaxis to its investment strategy, a decision anticipated to systematically enhance access to care and drive the need for improved diagnostic tracking in eligible nations. This strategic realignment targets the significant economic impact of the disease; the U.S. Department of Agriculture estimated in August 2024 that the aggregate annual costs for rabies detection, prevention, and control in the United States alone exceed $500 million.

Simultaneously, technological progress in molecular and lateral flow diagnostic assays is widening market access by providing fast, affordable options adaptable to various testing settings. Manufacturers are vigorously creating and releasing immunoassay-based solutions that decrease dependence on sophisticated laboratory setups, thereby boosting testing rates in both veterinary and human health sectors. For example, BioStone Animal Health reported in February 2024 the commercial release of the AsurDx Rabies Antibody Test Kit, an ELISA-based product engineered for the swift identification of rabies virus antibodies in mammalian serum. These innovations are essential to satisfy the increasing requirement for effective vaccine monitoring and disease surveillance, ensuring diagnostic capacities align with global elimination targets.

Market Challenge

The substantial expense associated with sophisticated diagnostic technologies, coupled with the scarcity of laboratory infrastructure in developing countries, presents a significant barrier to the growth of the Global Rabies Diagnostics Market. Although advanced techniques like Polymerase Chain Reaction (PCR) and Direct Fluorescent Antibody (DFA) testing provide superior sensitivity, they necessitate heavy capital expenditure on machinery, reliable power supplies, and specialized personnel. These prerequisites are frequently missing in low-resource areas where the disease is most endemic, creating an economic divide that effectively blocks the adoption of dependable testing kits and compels healthcare systems to rely on clinical observation rather than purchasing diagnostic solutions.

Consequently, the market struggles to penetrate regions that theoretically possess the highest patient volumes, thereby confining revenue generation primarily to developed nations with mature surveillance networks. This failure to secure a position in high-burden countries dampens global transaction volumes and discourages manufacturers from scaling distribution networks in emerging economies. According to the World Health Organization, the global economic burden of rabies was estimated at approximately US$ 8.6 billion annually in 2024, a statistic that underscores the profound financial restrictions limiting the ability of these health systems to fund essential diagnostic procurement.

Market Trends

The market is increasingly prioritizing genomic sequencing and variant typing over simple presence-absence detection to support precise epidemiological tracking. Laboratories are shifting from traditional Direct Fluorescent Antibody (DFA) testing toward molecular characterization to identify specific viral lineages and monitor cross-species transmission pathways. This evolution allows public health authorities to distinguish between indigenous and translocated variants, which is crucial for targeted intervention strategies in non-endemic zones. According to the American Veterinary Medical Association, July 2025, in the 'Rabies surveillance in the United States during 2023' report, 35.6% of all positive rabies samples underwent virus characterization to identify specific variants, underscoring the growing reliance on advanced molecular insights for disease management.

There is a distinct trend toward widening surveillance architectures to capture wildlife reservoirs that pose a persistent threat to urban and peri-urban populations. Unlike traditional models focused on domestic animals, these expanded networks focus on monitoring distinct wildlife vectors such as bats and foxes, which serve as primary reservoirs in regions where dog-mediated rabies is controlled. This shift necessitates the integration of regional data into broader national tracking systems to detect spillover events early. For instance, according to the Canadian Animal Health Surveillance System, February 2025, in the 'Status Update for Rabies' report, confirmed cases of bat variant rabies in Ontario reached 91 in 2024, highlighting the critical need for sustained wildlife monitoring to prevent reintroduction into domestic populations.

Key Market Players

  • Bio-Rad Laboratories, Inc
  • Merck KGaA
  • Aviva Systems Biology Corporation.
  • Creative Diagnostics
  • Demeditec Diagnostics GmbH.
  • Abbexa Ltd.
  • Norgen Biotek Corp.
  • BioNote, Inc.
  • Express Biotech International Inc.

Report Scope

In this report, the Global Rabies Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rabies Diagnostics Market, By Diagnostic Method

  • Fluorescent Antibody Test (FAT)
  • Immunohistochemical Test
  • Amplification Methods
  • Histologic Examination
  • Serology Tests

Rabies Diagnostics Market, By Technology Method

  • ELISA/Immunohistochemistry
  • Chromatography Techniques
  • PCR
  • Others

Rabies Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rabies Diagnostics Market.

Available Customizations:

Global Rabies Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rabies Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnostic Method (Fluorescent Antibody Test (FAT), Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests)
    • 5.2.2. By Technology Method (ELISA/Immunohistochemistry, Chromatography Techniques, PCR, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Rabies Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnostic Method
    • 6.2.2. By Technology Method
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rabies Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnostic Method
        • 6.3.1.2.2. By Technology Method
    • 6.3.2. Canada Rabies Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnostic Method
        • 6.3.2.2.2. By Technology Method
    • 6.3.3. Mexico Rabies Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnostic Method
        • 6.3.3.2.2. By Technology Method

7. Europe Rabies Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnostic Method
    • 7.2.2. By Technology Method
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rabies Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnostic Method
        • 7.3.1.2.2. By Technology Method
    • 7.3.2. France Rabies Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnostic Method
        • 7.3.2.2.2. By Technology Method
    • 7.3.3. United Kingdom Rabies Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnostic Method
        • 7.3.3.2.2. By Technology Method
    • 7.3.4. Italy Rabies Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Diagnostic Method
        • 7.3.4.2.2. By Technology Method
    • 7.3.5. Spain Rabies Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Diagnostic Method
        • 7.3.5.2.2. By Technology Method

8. Asia Pacific Rabies Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnostic Method
    • 8.2.2. By Technology Method
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rabies Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnostic Method
        • 8.3.1.2.2. By Technology Method
    • 8.3.2. India Rabies Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnostic Method
        • 8.3.2.2.2. By Technology Method
    • 8.3.3. Japan Rabies Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnostic Method
        • 8.3.3.2.2. By Technology Method
    • 8.3.4. South Korea Rabies Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnostic Method
        • 8.3.4.2.2. By Technology Method
    • 8.3.5. Australia Rabies Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnostic Method
        • 8.3.5.2.2. By Technology Method

9. Middle East & Africa Rabies Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnostic Method
    • 9.2.2. By Technology Method
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rabies Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnostic Method
        • 9.3.1.2.2. By Technology Method
    • 9.3.2. UAE Rabies Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnostic Method
        • 9.3.2.2.2. By Technology Method
    • 9.3.3. South Africa Rabies Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnostic Method
        • 9.3.3.2.2. By Technology Method

10. South America Rabies Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnostic Method
    • 10.2.2. By Technology Method
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rabies Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnostic Method
        • 10.3.1.2.2. By Technology Method
    • 10.3.2. Colombia Rabies Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnostic Method
        • 10.3.2.2.2. By Technology Method
    • 10.3.3. Argentina Rabies Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnostic Method
        • 10.3.3.2.2. By Technology Method

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rabies Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bio-Rad Laboratories, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck KGaA
  • 15.3. Aviva Systems Biology Corporation.
  • 15.4. Creative Diagnostics
  • 15.5. Demeditec Diagnostics GmbH.
  • 15.6. Abbexa Ltd.
  • 15.7. Norgen Biotek Corp.
  • 15.8. BioNote, Inc.
  • 15.9. Express Biotech International Inc.

16. Strategic Recommendations

17. About Us & Disclaimer